Salbutamol delays human eosinophil apoptosis via a cAMP-dependent mechanism

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 4, 2011, Pages 394-400

  Kankaanranta, Hannu ^a,b,c   Parkkonen, Jouni ^a,b   Ilmarinen Salo, Pinja ^a,b   Giembycz, Mark A ^d   Moilanen, Eeva ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Apoptosis; CAMP; Eosinophils; Salbutamol

Indexed keywords

8 BROMO CYCLIC AMP; 9 (TETRAHYDRO 2 FURYL)ADENINE; APAMIN; BUCLADESINE; CHARYBDOTOXIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIBUTYRYL CYCLIC GMP; IBERIOTOXIN; LIPOCORTIN 5; PAXILLINE; PROPRANOLOL; ROLIPRAM; SALBUTAMOL;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DNA FRAGMENTATION; EOSINOPHIL; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ADENYLATE CYCLASE; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; AMINO ACID SEQUENCE; APOPTOSIS; BUCLADESINE; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EOSINOPHILS; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHODIESTERASE INHIBITORS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED;

EID: 79956151092     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.03.002     Document Type: Article

References (38)

1. Watt A.P., Schock B.C., Ennis M. Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr Drug Targets Inflamm Allergy 2005, 4:415-423.
2. Kankaanranta H., Moilanen E., Zhang X. Pharmacological regulation of human eosinophil apoptosis. Curr Drug Targets Inflamm Allergy 2005, 4:433-445.
3. Giembycz M.A., Lindsay M.A. Pharmacology of the eosinophil. Pharmacol Rev 1999, 51:213-340.
4. Ward C., Dransfield I., Chilvers E.R., Haslett C., Rossi A.G. Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets. Trends Pharmacol Sci 1999, 20:503-509.
5. Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 1999, 160:5-11.
6. Walsh G.M., Sexton D.W., Blaylock M.G. Mechanisms of steroid action and resistance in inflammation. Corticosteroids, eosinophils and epithelial cells: new insights into the resolution of inflammation in asthma. J Endocrinol 2003, 178:37-43.
7. Kankaanranta H., Lindsay M.A., Giembycz M.A., Zhang X., Moilanen E., Barnes P.J. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 2000, 106:77-83.
8. Wedi B., Raap U., Lewrick H., Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997, 100:536-543.
9. Vignola A.M., Chanez P., Chiappara G., Siena L., Merendino A., Reina C. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol 1999, 103:563-573.
10. Nelson H.S. Is there a problem with inhaled long-acting β-adrenergic agonists?. J Allergy Clin Immunol 2006, 117:3-16.
11. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26. The SMART study group.
12. Machida K., Inoue H., Matsumoto K., Tsuda M., Fukuyama S., Koto H., et al. Activation of PI3K-Akt pathway mediates antiapoptotic effects of β-adrenergic agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol 2005, 288:L860-L867.
13. Hallsworth M.P., Giembycz M.A., Barnes P.J., Lee T.H. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. Br J Pharmacol 1996, 117:79-86.
14. Momose T., Okubo Y., Horie S., Suzuki J., Isobe M., Sekiguchi M. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression. Int Arch Allergy Immunol 1998, 117:138-145.
15. Chang H.S., Jeon K.W., Kim Y.H., Chung I.Y., Park C.S. Role of cAMP-dependent pathway in eosinophil apoptosis and survival. Cell Immunol 2000, 203:29-38.
16. Peacock C.D., Misso N.L., Watkins D.N., Thompson P.J. PGE 2 and dibutyryl cyclic adenosine monophosphate prolong eosinophil survival in vitro. J Allergy Clin Immunol 1999, 104:153-162.
17. Parkkonen J., Hasala H., Moilanen E., Giembycz M.A., Kankaanranta H. Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol. Pulm Pharmacol Ther 2008, 21:499-506.
18. Zhang X., Moilanen E., Lahti A., Hämäläinen M., Giembycz M.A., Barnes P.J., et al. Regulation of eosinophil apoptosis by nitric oxide: role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5. J Allergy Clin Immunol 2003, 112:93-101.
19. Kankaanranta H., Ilmarinen P., Zhang X., Nissinen E., Moilanen E. Antieosinophilic activity of orazipone. Mol Pharmacol 2006, 69:1861-1870.
20. Kankaanranta H., De Souza P.M., Barnes P.J., Salmon M., Giembycz M.A., Lindsay M.A. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 1999, 290:621-628.
21. Ilmarinen P., Hasala H., Sareila O., Moilanen E., Kankaanranta H. Bacterial DNA delays human eosinophil apoptosis. Pulm Pharmacol Ther 2009, 22:167-176.
22. Giembycz M.A., Newton R. Beyond the dogma: novel β2-adrenoceptor signalling in the airways. Eur Respir J 2006, 27:1286-1306.
23. Dostmann W.R.G., Taylor S.S., Genieser H.-G., Døskeland S.O., Øgreid D. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinase I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J Biol Chem 1990, 265:10484-10491.
24. Gjertsen B.T., Mellgren G., Otten A., Maronde E., Genieser H.-G., Jastorff B., et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. J Biol Chem 1995, 270:20599-20607.
25. Baviera A.M., Zanon N.M., Navegantes L.C., Kettelhut I.C. Involvement of cAMP/Epac/PI3K-dependent pathway in the antiproteolytic effect of epinephrine on rat skeletal muscle. Mol Cell Endocrinol 2010, 315:104-112.
26. Sousa L.P., Lopes F., Silva D.M., Tavares L.P., Vieira A.T., Rezende B.M., et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kB-independent manner. J Leukoc Biol 2010, [Epub ahead of print].
27. Bjørgo E., Solheim S.A., Abrahamsen H., Baillie G.S., Brown K.M., Berge T., et al. Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase A signalling pathways at the level of a protein kinase B/β-arrestin/cAMP phosphodiesterase 4 complex. Mol Cell Biol 2010, 30:1660-1672.
28. Jonkman J.H.G., Freie H.M.P., van der Boon W.J.V., Grasmeijer G. Single dose absorption profiles and bioavailability of two different salbutamol tablets. Arzneimittelforschung 1986, 36:1133-1135.
29. Powell M.L., Chung M., Weisberger M., Gural R., Radwanski E., Symchowicz S., et al. Multiple-dose albuterol kinetics. J Clin Pharmacol 1986, 26:643-646.
30. Hochhaus G., Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the β2-agonist terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol 1992, 30:342-362.
31. Nuesslein T.G., Wallis H., Stephan V., Rieger C. Measurement of the deposition of salbutamol in the bronchial lavage fluid of infants and young children. Pneumologie 2003, 57:433-438.
32. Rabe K.F., Linden A. Beta2-agonists in asthma treatment, lung biology in health and disease 1997, vol. 106:131-160. R. Pauwels, P.M. O'Byrne (Eds.).
33. Levi-Schaffer F., Temkin V., Malamud V., Feld S., Zilberman Y. Mast cells enhance eosinophil survival in vitro: role of TNF-α and granulocyte macrophage colony-stimulating factor. J Immunol 1998, 160:5554-5562.
34. Valerius T., Repp R., Kalden J.R., Platzer E. Effects of IFN on human eosinophils in comparison with other cytokines. J Immunol 1990, 145:2950-2958.
35. Manolitsas N.D., Wang J., Devalia J.L., Trigg C.J., McAulay A.E., Davies R.J. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am J Respir Crit Care Med 1995, 151:1925-1930.
36. Gauvreau G.M., Jordana M., Watson R.M., Cockroft D.W., O'Byrne P.M. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997, 156:1738-1745.
37. Swystun V.A., Gordon J.R., Davis E.B., Zhang X., Cockroft D.W. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol 2000, 106:57-64.
38. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008, 155:308-315.